


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A phenoxypropylamine compound of the formula (I)



wherein each symbol in the formula means as follows:


a bond represented by a solid line and a dotted line shows a double bond or a single bond;

X is a hydrogen atom, a hydroxy group, a C₁-C₈ alkoxy group, an acyloxy group or an oxo group;

provided that when R¹ is a group of the following formula (2),

X should not be a hydrogen atom;

R¹ is a group of the following formula



wherein

Y is O or S;

Ar is optionally substituted aromatic hydrocarbon;

R² is optionally substituted aryl group or optionally substituted aromatic heterocyclic group;


R⁵ is optionally substituted aryl group or optionally substituted aromatic heterocyclic group;

- Z is void or $-\text{CH}_2-$, and
- R^6 is hydrogen atom, hydroxy group, acetamido group, carboxyl group, alkoxycarbonyl group, cyano group or $\text{C}_1\text{-C}_8$ alkoxy group;
- R^3 is a hydrogen atom, a $\text{C}_1\text{-C}_{18}$ alkyl group or a halogen atom;
- V is $-\text{CH}_2-$, $-\text{O}-$, $-\text{S}-$ or the formula $-\text{N}(\text{R}^*)-$ wherein R^* is hydrogen atom, $\text{C}_1\text{-C}_{18}$ alkyl group or optionally substituted aralkyl group;
- W is void or $-\text{CH}_2-$ or $-\text{C}(=\text{O})-$;
- R^7 is a $\text{C}_1\text{-C}_4$ hydroxyalkyl group, an acyl group, an optionally substituted saturated or unsaturated heterocyclic group, an optionally substituted fused heterocyclic group, a $\text{C}_1\text{-C}_4$ alkylsulfonyl group or the formula $-\text{Q-R}^9$


wherein

Q is $-\text{C}(=\text{O})-$, $-\text{C}(=\text{S})-$, $-\text{CH}_2-$ or $-\text{S}(=\text{O})_2-$, and


R^9 is a group of the following formula




(5)




(6)




(7)




(8)




(9)




(10)



(11)



(12)




(13)

or -NH-NH-R¹⁵

wherein R¹⁰ and R¹¹ are each independently hydrogen atom, C₁-C₁₈ alkyl group, optionally substituted aryl group, optionally substituted aralkyl group or alkoxy group, R¹² is hydrogen atom, optionally substituted aryl group, C₁-C₁₈ alkyl group, C₁-C₈ alkoxy group or acyl group, and R¹⁵ is hydrogen atom, phenyl group, C₁-C₄ alkyl group, C₁-C₂ halogenated alkyl group, halogen atom, C₂-C₄ alkenyl group, C₁-C₄ hydroxyalkyl group, alkoxyalkyl group, alkyloxycarbonyl group, optionally substituted amino group, acetamido group, carboxyl group, acyl group, optionally substituted alkyloxy group, alkylthio group or cyano group;

~~provided that when R⁷ is a group of the above formula (2), R⁷ should not be C₁-C₄ hydroxyalkyl group or acyl group, and R¹⁰ and R¹¹ are not each hydrogen atom at the same time; or~~

~~R⁷ and W in combination may form a ring of the following formula-~~



wherein-

~~E — is oxygen atom or sulfur atom, and~~


~~Q' — is an optionally substituted 4 to 7-membered heterocycle having 1 or 2 hetero atom(s) selected from the group consisting of nitrogen atom and oxygen atom in the ring, in which case V is hydrogen atom; and~~

~~R_a, R_b and R_c are each independently a hydrogen atom, a C₁-C₁₈ alkyl group, a hydroxy group, a C₁-C₈ alkoxy group, a halogen atom, an acyl group, a nitro group or an amino group;~~

~~provided that when R⁷ and W are bonded to form a ring of the above formula (14), R_a, R_b and R_c are not each hydroxy group or C₁-C₈ alkoxy group;~~

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

2. (Currently Amended) The compound of the claim 1, which is represented by the formula (I)




wherein each symbol in the formula means as follows:

a bond represented by a solid line and a dotted line shows a double bond;

X is a hydrogen atom, a hydroxy group, a C₁-C₈ alkoxy group, an acyloxy group or an oxo group;

R¹ is a group of the following formula



wherein

~~Y~~ is ~~O or S~~;

~~Ar~~ is ~~optionally substituted benzene or naphthalene~~;

~~R²~~ is ~~optionally substituted aryl group or optionally substituted aromatic heterocyclic group~~;

R⁵ is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

Z is void or -CH₂-, and

R⁶ is hydrogen atom, hydroxy group, acetamido group, carboxyl group, alkoxy carbonyl group, cyano group or C₁-C₈ alkoxy group;

R³ is a hydrogen atom, a C₁-C₁₈ alkyl group or a halogen atom;

V is ~~-CH₂-, -O-, -S- or the formula -N(R^{*})-~~ wherein ~~R^{*} is hydrogen atom, C₁-C₁₈ alkyl group or optionally substituted aralkyl group~~;


W is void or ~~-CH₂- or -C(=O)-~~;

R⁷ is a C₁-C₄ hydroxyalkyl group, an acyl group, an optionally substituted saturated or unsaturated heterocyclic group, an optionally substituted fused heterocyclic group, a C₁-C₄ alkylsulfonyl group or the formula -Q-R⁹


wherein

Q is -C(=O)-, -C(=S)-, -CH₂- or -S(=O)₂-, and


R⁹ is a group of the following formula




(5)




(6)



(7)






(8)



(9)



(10)



or -NH-NH-R¹⁵

wherein R¹⁰ and R¹¹ are each independently hydrogen atom, C₁-C₁₈ alkyl group, optionally substituted aryl group, optionally substituted aralkyl group or alkoxy group, R¹² is hydrogen atom, optionally substituted aryl group, C₁-C₁₈ alkyl group, C₁-C₈ alkoxy group or acyl group, and R¹⁵ is hydrogen atom, phenyl group, C₁-C₄ alkyl group, C₁-C₂ halogenated alkyl group, halogen atom, C₂-C₄ alkenyl group, C₁-C₄ hydroxyalkyl group, alkoxyalkyl group, alkyloxycarbonyl group, optionally substituted amino group, acetamido group, carboxyl group, acyl group, optionally substituted alkyloxy group, alkylthio group or cyano group; and

R_a, R_b and R_c are each independently a hydrogen atom, a C₁-C₁₈ alkyl group, a hydroxy group, a


C₁-C₈ alkoxy group, a halogen atom, an acyl group, a nitro group or an amino group; provided that when R[†] is a group of the above formula (2), R[†] should not be C₁-C₄ hydroxyalkyl group or acyl group, and R^{††} and R^{††} are not each hydrogen atom at the same time; an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

3. (Currently Amended) The compound of the claim 2, which is represented by the formula (I) wherein each symbol in the formula means as follows:

a bond represented by a solid line and a dotted line shows a double bond;

X is a hydroxy group;

R^1 is a group of the following formula



wherein

R^5 is optionally substituted phenyl group or naphthyl group,

Z is void, and

R^6 is hydrogen atom;





R^3 is a hydrogen atom or a C_1-C_4 alkyl group;

V is $-\text{CH}_2-$, $-\text{O}-$, $-\text{S}-$ or $-\text{N}(\text{R}^*)-$

wherein R^* is hydrogen atom, C_1-C_6 alkyl group or optionally substituted aralkyl group;

W is void;

R^7 is a group of the following formula








or the formula $-\text{CO}-\text{R}^9$


wherein

R^8 is hydrogen atom, phenyl group, C_1 - C_4 alkyl group, C_1 - C_2 halogenated alkyl group, halogen atom, C_2 - C_4 alkenyl group, C_1 - C_4 hydroxyalkyl group, alkoxyalkyl group, alkyloxycarbonyl group, optionally substituted amino group, acetamido group, carboxyl group, acyl group, optionally substituted alkyloxy group, alkylthio group or cyano group, and

R^9 is a group of the following formula



or




wherein R^{10} and R^{11} are each independently hydrogen atom, C_1 - C_{18} alkyl group, optionally substituted aryl group, optionally substituted aralkyl group or alkoxy group, and R^{12} is hydrogen atom, optionally substituted aryl group, C_1 - C_{18} alkyl group, C_1 - C_8 alkoxy group or acyl group; and

R_a , R_b and R_c are each a hydrogen atom;

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

4. (Previously Amended) The compound of claim 2 ~~or claim 6~~, which is represented by the formula (I')



wherein each symbol is as in claim 2,
an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

5. (Currently Amended) The compound of claim 2, which is selected from the group consisting of

- (1) 1-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)benzo(b)furan-2-ylcarbonyl)pyrrolidine,
- (2) 4-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)benzo(b)furan-2-ylcarbonyl)morpholine,
- (4) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-N,N-dimethylbenzo(b)furan-2-carboxamide,
- (12) 1-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)benzo(b)thiophen-2-ylcarbonyl)pyrrolidine,
- (13) 4-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)benzo(b)thiophen-2-ylcarbonyl)morpholine,

(15) 4-(2-hydroxy-3-(4-(naphthalen-1-yl)piperidino)propyloxy)-N,N-dimethylbenzo(b)thiophene-2-carboxamide,-

(17) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-N,N-dimethylbenzo(b)thiophene-2-carboxamide,-

(20) 4-(7-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)benzo(b)furan-2-ylcarbonyl)morpholine,

(21) 7-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-N,N-dimethylbenzo(b)furan-2-carboxamide,

(27) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-N,N-dimethyl-1H-indole-2-carboxamide,-

(30) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-N,N-dimethyl-1-methylindole-2-carboxamide,-

(35) 1-(2-(5-methyl-1,2,4-oxadiazol-3-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(37) 1-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(38) 1-(2-(5-trifluoromethyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(39) 1-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-7-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(42) 1-(2-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-indole-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,-

(44) 1-(2-(3-methyl-1,2,4-oxadiazol-5-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(48) 1-(2-(5-methyloxazol-2-yl)benzo(b)furan-7-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,

(81) 3-(4-(3,4-dichlorophenyl)piperidino)-1-(2-(5-methyloxazol-2-yl)benzo(b)furan-4-yloxy)-2-propanol,

(88)1-(4-(3,4-dichlorophenyl)piperidino)-3-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-2-propanol, and

(93)3-(4-(3,4-dimethylphenyl)piperidino)-1-(2-(5-ethyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-2-propanol,


an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

6-12. (Deleted)

13. (Original) A pharmaceutical composition comprising at least one member selected from the group consisting of a compound of claim 1, an optically active compound thereof, a pharmaceutically acceptable salt thereof and a hydrate thereof, and a pharmaceutically acceptable carrier.

14-16. (Deleted)

17. (Currently Amended) A compound of the formula (II)




wherein each symbol in the formula means as follows:

X is a hydrogen atom, a hydroxy group, a C_1 - C_8 alkoxy

group or an acyloxy group or an oxo group;

R^1 is a group of the following formula



wherein

Y is O or S;

Ar is optionally substituted benzene or naphthalene;

R^2 is optionally substituted aryl group or optionally substituted aromatic heterocyclic group;

R^5 is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

Z is void or $-CH_2-$, and

R^6 is hydrogen atom, hydroxy group, acetamido group, carboxyl group, alkoxycarbonyl group, cyano group or C_1-C_8 alkoxy group;

provided that when V is $-N(R^*)$, R^6 should not be hydroxy group;

R^3 is a hydrogen atom, a C_1-C_{18} alkyl group or a halogen atom;

V is $-CH_2-$, $-O-$, $-S-$ or the formula $-N(R^*)$;

wherein

R^* is hydrogen atom, C_1-C_{18} alkyl group or optionally substituted aralkyl group;

W is void, $-CH_2-$ or $-C(=O)-$;


R^{14} is a hydrogen atom or a C_1-C_4 alkyl; and

Ra , Rb and Rc are each independently a hydrogen atom, a C_1-C_{18} alkyl group, a hydroxy group, a C_1-C_8 alkoxy group, a halogen atom, an acyl group, a nitro group or an amino group;

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

18-20. (Deleted)

21. (Currently Amended) The compound of claim 3, which is represented by the formula (I')



wherein each symbol is as in claim 2 3,

an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

22. (New) A method of treating depression, which comprises administering, to a mammal, an effective amount of a compound of claim 1, an optically active compound thereof, pharmaceutically acceptable salt thereof or a hydrate thereof.

23. (New) 2-(4-hydroxybenzo(b)furan-2-yl)-5-methyl-1,3,4-oxadiazole.

24. (New) (S)-2-(4-glycidyoxybenzo(b)furan-2-yl)-5-methyl-1,3,4-oxadiazole.